JHMV N1347A has decreased replication in the olfactory bulbs of mice. by Catherine M. Kerr (21492574)

LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

Table 3_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.xlsx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”

Table 1_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”

Table 2_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

“…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”

NANOG has glycosylation sites. by Yin Tian (181303)

The Ishihara test for colourblindness [41] encompasses stimuli that can determine the degree and type of colourblindness a person has. by Marcel F. Hinss (14675457)

OPG147 has no effect on TBK1 or IRF3-mediated ISRE activation and HT-DNA-induced signaling. by Xue-Mei Yi (18851202)

The presence of the gRNA targeting <i>OPG147</i> has no effect on transcription of viral entry and early genes. by Xue-Mei Yi (18851202)

Biomimetic Topological Micropattern Arrays Regulate the Heterogeneity of Cellular Fates in Lung Fibroblasts between Fibrosis and Invasion by Xinglong Zhu (11896815)

Subjects:

HAstV-8 (D471S, N512D) spike has decreased or no binding to FcRn compared to wild-type HAstV-8 spike. by Catalina Aguilera-Flores (21743843)

Adult demyelination has no effect on PV interneuron’s firing rate or failures in autaptic responses. by Sara Hijazi (21656615)

IGF-1 has no effect on plaque burden on irradiated mice. by Patricia Snarski (22305205)

IGF-1 has no effect on plaque burden on irradiated mice. by Patricia Snarski (22305205)

<i>S</i>. Paratyphi A has deficient L O-ag production due to R98C mutation in WzzB. by Fermin E. Guerra (6084545)

Noise decrease rate comparison. by Xianlin Ren (22783589)

Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae by Ziyuan Zhao (2889005)

“…We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …”